West Pharmaceutical Services (WST) is down 4.6% today. Here is some analysis on what might have caused this price movement.
Analysis: The decline appears tied to investors digesting a newly announced CEO retirement plan and a follow-on investor conference appearance that didn’t introduce a fresh positive catalyst. Leadership-transition uncertainty can pressure valuation for high-multiple healthcare suppliers, and the move also looks consistent with short-term “sell-the-news” trading after prior strength.
Details:
Sources:
PR Newswire, Investing.com, Morningstar
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$WST Hedge Fund Activity
We have seen 360 institutional investors add shares of $WST stock to their portfolio, and 419 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,635,288 shares (-74.4%) from their portfolio in Q4 2025, for an estimated $725,073,140
- DURABLE CAPITAL PARTNERS LP removed 1,172,583 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $322,624,486
- LONGVIEW PARTNERS (GUERNSEY) LTD added 778,887 shares (+221.2%) to their portfolio in Q4 2025, for an estimated $214,302,969
- VAN ECK ASSOCIATES CORP removed 708,792 shares (-49.7%) from their portfolio in Q4 2025, for an estimated $195,017,030
- GENERATION INVESTMENT MANAGEMENT LLP added 585,855 shares (+60.0%) to their portfolio in Q4 2025, for an estimated $161,192,144
- BROWN ADVISORY INC removed 554,476 shares (-22.2%) from their portfolio in Q4 2025, for an estimated $152,558,526
- CITADEL ADVISORS LLC removed 481,897 shares (-66.2%) from their portfolio in Q4 2025, for an estimated $132,589,140
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$WST Analyst Ratings
Wall Street analysts have issued reports on $WST in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 10/29/2025
- Keybanc issued a "Overweight" rating on 10/24/2025
- UBS issued a "Buy" rating on 10/24/2025
- Evercore ISI Group issued a "Outperform" rating on 10/23/2025
- Rothschild & Co issued a "Buy" rating on 09/15/2025
To track analyst ratings and price targets for $WST, check out Quiver Quantitative's $WST forecast page.
$WST Price Targets
Multiple analysts have issued price targets for $WST recently. We have seen 7 analysts offer price targets for $WST in the last 6 months, with a median target of $320.0.
Here are some recent targets:
- Luke Sergott from Barclays set a target price of $265.0 on 02/13/2026
- Daniel Markowitz from Evercore ISI Group set a target price of $320.0 on 02/03/2026
- Kallum Titchmarsh from Morgan Stanley set a target price of $285.0 on 12/02/2025
- Brendan Smith from TD Cowen set a target price of $350.0 on 10/29/2025
- John Sourbeer from UBS set a target price of $355.0 on 10/24/2025
- Paul Knight from Keybanc set a target price of $350.0 on 10/24/2025
- Jamie Clark from Rothschild & Co set a target price of $311.0 on 09/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
